exRNAdisease

General Information

Database ID:

exR0079629

RNA Name:

PRRC2B

RNA Type:

mRNA

Chromosome:

chr9

Starnd:

Coordinate:

Start Site(bp):

131373636

End Site(bp):

131500197

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AAK1	chr2	69457997	69674349	-
ABCB6	chr2	219209772	219218994	-
ABLIM1	chr10	114431113	114768061	-
AC011511.4	chr19	10315471	10320678	-
AC068946.2	chr2	219209772	219222738	-
AC245033.1	chr15	82536788	82573194	-
ACTN4	chr19	38647649	38731589	+
ACTR2	chr2	65227753	65271253	+
ADIPOR1	chr1	202940826	202958572	-
AFDN	chr6	167826922	167972023	+
AFF4	chr5	132875395	132963634	-
AGAP5	chr10	73674285	73698159	-
AGRN	chr1	1020120	1056118	+
AHCY	chr20	34280268	34311802	-
AHNAK2	chr14	104937244	104978374	-
AKT2	chr19	40230317	40285536	-
AL024498.2	chr6	10747794	10930423	+
AL121594.1	chr14	35122549	35317474	+
ALCAM	chr3	105366909	105576900	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-31-5p	chr9	21512158	21512178	-
hsa-miR-147a	chr9	120244985	120245004	-
hsa-miR-217-5p	chr2	55983020	55983042	-
hsa-miR-135a-5p	chr12	97563834	97563856	+
hsa-miR-135b-5p	chr1	205448361	205448383	-
hsa-miR-483-3p	chr11	2134142	2134162	-
hsa-miR-520a-5p	chr19	53690895	53690915	+
hsa-miR-525-5p	chr19	53697547	53697567	+
hsa-miR-650	chr22	22822791	22822811	+
hsa-miR-423-5p	chr17	30117095	30117117	+
hsa-miR-541-3p	chr14	101064548	101064569	+
hsa-miR-1286	chr22	20249145	20249165	-
hsa-miR-1294	chr5	154347153	154347174	+
hsa-miR-1321	chrX	85835832	85835849	+
hsa-miR-5100	chr10	42997630	42997651	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC005082.1	chr7	23205787	23208045	+
AC022400.3	chr10	73674295	73730466	-
AC109460.3	chr16	28974804	28990775	+
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference